Trial Search Results

Acute Treatment of Bipolar II Depression

This study will compare the medications lithium and lamotrigine (Lamictal®) in treating depression in individuals with bipolar II disorder.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Stanford University

Collaborator: National Institute of Mental Health (NIMH)

Stanford Investigator(s):

Intervention(s):

  • Drug: Lithium
  • Drug: Lamotrigine

Phase:

Phase 3

Eligibility


Inclusion Criteria:

   - Current diagnosis of bipolar II disorder

Exclusion Criteria:

   - Use of lithium or lamotrigine

   - Intolerance to lithium or lamotrigine

   - Substance abuse or dependence within the last month

   - Suicidal thoughts

   - Unstable medical conditions

   - Pregnancy or breast-feeding

   - Stable on current medications

   - Use of fluoxetine (Prozac) within 2 weeks of study

   - Require an antipsychotic medication

   - Do not speak or read English

Ages Eligible for Study

18 Years - 55 Years

Genders Eligible for Study

All

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting